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Search strategy and selection criteria
References for this review were identiﬁed from sear-
ches of Pubmed (from 1966 to 2005) and the Coch-
rane Library (2005, Issue 2) with the search terms
‘‘multiple sclerosis’’, ‘‘tremor’’, ‘‘ataxia’’, ‘‘disability’’,
‘‘prevalence’’, ‘‘surgery’’, ‘‘thalamotomy’’, ‘‘deep brain
stimulation’’ and ‘‘treatment’’. Articles were also
identiﬁed through searches of the reference tables of
identiﬁed papers. Furthermore we searched the ISI
Science Citation Index for relevant articles citing
identiﬁed papers. Only articles in English and German
were included in the review; publications in abstract
form were not considered.
Introduction
Tremor is such a common problem in multiple scle-
rosis (MS) that the famous French neurologist Char-
cot (1825–1893) described it as a part of his triad of
characteristic symptoms in MS, together with nys-
tagmus, and scanning speech.
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j Abstract Tremor is estimated to
occur in about 25 to 60 percent of
patients with multiple sclerosis
(MS). This symptom, which can be
severely disabling and embarrass-
ing for patients, is difﬁcult to
manage. Isoniazid in high doses,
carbamazepine, propranolol and
gluthetimide have been reported
to provide some relief, but pub-
lished evidence of effectiveness is
very limited. Most trials were of
small size and of short duration.
Cannabinoids appear ineffective.
Tremor reduction can be obtained
with stereotactic thalamotomy or
thalamic stimulation. However,
the studies were small and infor-
mation on long-term functional
outcome is scarce. Physiotherapy,
tremor reducing orthoses, and
limb cooling can achieve some
functional improvement. Tremor
in MS remains a signiﬁcant chal-
lenge and unmet need, requiring
further basic and clinical research.
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in MS is often frustrating. In this review we discuss
medical, surgical and other treatment options.
j Epidemiology
Although the epidemiology of symptoms in MS has
been studied extensively, it remains difﬁcult to
ascertain the prevalence of tremor in historic study
populations, mostly because Kurtzke’s functional
systems scale for cerebellar function, which is most
widely used in clinical studies in MS, does not record
tremor [55]. In a large long-term follow-up study,
Weinshenker and colleagues found functionally rele-
vant cerebellar deﬁcits in one third of 259 patients
[94]. In another study, disability and dependency of
patients with MS were shown to correlate with the
severity of ataxia [95].
Two newer studies assessed the prevalence of tre-
mor in MS. One study by Alusi and coworkers
examined 100 patients randomly selected from a
London MS-clinic and found tremor in 58% of pa-
tients. The tremor was minimal in 27%, mild in 16%
and moderate to severe in 15% of all patients [6]. As
patients were selected from a specialist clinic, the
relatively high prevalence and severity of tremor
might be due to selection bias.
In a prevalence cohort study by Pittock and col-
leagues, 200 MS patients living in Olmsted County,
Minnesota, USA were assessed for tremor and mea-
sures of disability. Tremor was found in 25.5% and
severe tremor in 3% of the study population [74].
Probably the community based population in the
latter study gives a more realistic estimate of tremor
prevalence in MS. In both studies, however, tremor
was associated with greater disability as measured on
the expanded disability status scale (EDSS). In the
Olmsted County population, patients with tremor of
any severity were more likely to be unemployed or
retired early because of disability.
j Tremor subtypes
Tremor in MS can involve the head, neck, vocal cords,
trunk and limbs, whereas involvement of the tongue,
jaw or palate has not been reported [5].
The different types of tremor are currently classi-
ﬁed according to a working consensus of the Move-
ment Disorder Society [29]. In MS, the two most
prevalent tremor forms are postural tremor (tremor
present whilst voluntarily maintaining a position
against gravity) and intention tremor (tremor occur-
ring during target directed movement where tremor
amplitude increases during visually guided move-
ments towards the target). True rest tremor (tremor
present in a body part that is not voluntarily activated
and is completely supported against gravity) is unu-
sual in patients with MS, and Holmes (or ‘‘rubral’’)
tremor is also very uncommon.
In the two main prevalence studies, [6, 74] rest
tremor was observed only in the Olmsted County
survey (1% of patients), whereas Holmes tremor was
observed in neither study. An overview of the affected
body parts observed in both studies is given in
Table 1. In both studies tremor was most commonly
found in the arms. In the London study population,
36% of patients suffered from bilateral arm tremor,
making this the most common pattern of limb
involvement.
j Pathophysiology of tremor
The pathophysiology of tremor in MS is a difﬁcult
area of investigation, partly because MS is by deﬁni-
tion a multifocal disease, so that tremor occurrence
cannot easily be linked to a single neuroanatomical
site. Systematic postmortem studies on the link
between lesion site and the clinical phenomenon of
tremor have never been undertaken.
The predominance of action tremors (postural and
intention) in patients with MS point to the cerebellum
and its connections as the most likely source of
tremor production, whereas the rarity of rest tremor
argues against an involvement of the basal ganglia.
The common occurrence of bilateral tremor might
indicate that damage to the cerebellum and its
connections is often multifocal.
Another link to the cerebellum in the pathophysi-
ology of tremor in MS is the effect of peripheral
cooling on intention tremor. Intention tremor is
thought to be modulated through increased long
latency stretch reﬂexes [30]. Cooling has been shown
to decrease the sensitivity of muscle spindles [64] and
the velocity of peripheral nerve conduction [56].
In two experimental studies, cooling of the arms
markedly reduced intention tremor severity in
patients with MS [77, 35]. The authors argue that this
effect might have been partly due to decreased muscle
Table 1 Details of the two main prevalence studies on tremor in MS
London [6]
(n = 100)
Olmsted
County [74]
(n = 200)
Total patients with tremor 58 (58%) 51 (25.5%)
Patients with severe tremor 15 (15%) 6 (3%)
Arm tremor 56 (56%) 47 (23.5%)
Bilateral arm tremor 36 (36%) not reported
Leg tremor 10 (10%) 12 (6%)
Head tremor 9 (9%) 7 (3.5%)
trunk tremor 7 (7%) not reported
134spindle function and decreased nerve conduction
velocity, which in turn resulted in decreased input
into tremor producing cerebellar circuits.
Alusi and coworkers drew attention to the place-
ment site of deep brain stimulation (DBS) electrodes
to help understand the neuronal circuits involved in
tremor production. They stated that neurosurgeons
increasingly chose the nucleus ventralis oralis
posterior (VOP) of the thalamus rather than the classic
target, the nucleus ventralis intermedius (VIM). This
is interesting because the VOP is the basal ganglia
output nucleus of the thalamus [6], suggesting that the
cerebellar tremors seen in MS might actually be gen-
erated by the basal ganglia. The standard electrode
placement site reported in the literature, however, is
the VIM and no studies comparing placement sites
have been published. Whittle and coworkers comment
on the difﬁculty of electrode placement in MS patients:
in most patients there are major brain distortions due
to demyelination, plaque formation and e vacuo
hydrocephalus, and it is therefore uncertain whether
the anatomy of these patients conforms to standard
stereotactic atlasses [100]. Keeping these comments in
mind, it seems unwise to base pathophysiological
theories purely on DBS electrode placement site.
A range of animal experiments have been under-
taken to indentify the anatomical structures involved
in tremor production (for review [101]). It has been
shown that damage or removal of the cerebellar
cortex does not induce intention tremor in monkeys,
[31, 76] whereas partial or complete cerebellectomy
leads to tremor during movement and posture [75, 42,
40]. A slow, 3–5 Hz tremor during target directed
movements can also be induced by reversible cooling
of the dentate nucleus (the origin of most cerebellar
efferents) in monkeys [22].
Most cerebellar efferents project from the dentate
nucleus via the superior cerebellar peduncle (brachi-
um conjunctivum) to the red nucleus and the thala-
mus. According to some studies, transection of the
superior cerebellar peduncle causes intention tremor
in monkeys [34, 93], whereas other authors do not
mention this effect.
Interestingly, Carpenter and colleagues report that
tremor induced by transection of the superior cere-
bellar peduncle can be alleviated by a second lesion in
the lateroventral or centromedian thalamus. [19, 20]
The results of these animal studies suggest that
damage to cerebellar efferents (through lesions of the
dentate nucleus or superior cerebellar peduncle) may
cause disinhibition of thalamic nuclei which are the
main producers of intention tremor.
Although this is an interesting pathophysiologic
model of intention tremor production, it remains
uncertain whether the results of animal studies can be
generalized to patients with MS.
In summary, clinical observation, animal studies
and some experimental evidence in humans favour
the cerebellum and the thalamic nuclei connected to it
as the major locus of intention tremor production,
but more research is needed to evaluate the role of the
basal ganglia and other systems in tremor production
in MS.
j Assessment of tremor
Depending on the subtype of tremor, several methods
for the assessment of tremor severity and its impact
on the lives of patients have been developed. Rest
tremor is often assessed with the tremor subscale of
the Uniﬁed Parkinson’s Disease Rating Scale (UP-
DRS). Fahn and colleagues devised the most com-
prehensive tremor scale for non-parkinsonian tremor
in 1984 [33]. This instrument measures tremor in nine
body parts at rest, while maintaining a posture and
during goal directed movements. It also includes an
assessment of arm tremor while writing and pouring
water as well as a subscale for functional disability
(interference of tremor with dressing, writing, eating
etc.). Some studies included in this review use a
modiﬁed and heavily abbreviated version of this scale,
but most studies assess tremor by clinical examina-
tion only (e.g. by ﬁnger-to-nose testing, drinking
from a cup, nine-hole-peg-test or writing and drawing
tasks) or use a simple ordinal severity scale, often
classifying tremor as absent, mild, moderate or se-
vere. A simple 0–10 tremor severity scale devised by
Bain and coworkers [11] has been shown to be a valid
and reliable measurement tool in patients with MS
[7], but has so far only been used in few clinical
studies [6, 4, 15].
Accelerometry and polarized light goniometry are
neurophysiologic methods of tremor assessment.
While these methods offer an objective measurement
of tremor severity, they can only measure one aspect
of an often complex movement problem at a time, and
e.g. cannot measure the ataxia which often compli-
cates tremor in MS.
Matsumoto and colleagues devised a more complex
‘‘quantitative movement analysis technique’’, which
records the patients’ goal directed movements in
three dimensions using an electromagnetic tracking
device, but the complexity of this method [62] as well
as the computer aided tracking tasks employed by
Aisen and coworkers [2] prohibit their widespread
use.
One of the most important aspects of tremor in MS
is its impact on the daily life of the patients. Functional
status in MS-patients is often measured by asking the
patients to complete questionnaires assessing activi-
ties of daily living such as writing, eating or dressing.
135Often these scales are self-devised and not validated.
Validated scales used in the studies reviewed in this
article include the Frenchay Activities Index [85] and
the quality of life subscale of the Functional Assess-
ment of Multiple Sclerosis Scale (FAMS) [62].
j Medical treatment
A summary of the published studies on medical
treatment of tremor in MS is given in Table 2. Most of
the published literature on medical treatment consists
of case reports and uncontrolled open label studies.
The few randomized controlled trials comprised small
numbers of patients and very likely lacked the power
to reveal small treatment effects.
Beneﬁcial effects have been reported for a variety
of drugs: case reports and small uncontrolled open
label studies claim a positive effect of primidone [47],
gluthetimide [2], intrathecal baclofen [96] and isoni-
azid. [80, 32, 67, 38] Controlled clinical trials have
been published on the use of propranolol [52], etha-
nol [52], isoniazid, [52, 44, 16] carbamazepine [86],
ondansetron [78] and dolasetron [65].
Koller evaluated the effect of propranolol, isoniazid
and ethanol on tremor in three tremulous MS patients
in a double blind crossover trial and found no treat-
menteffectforanyofthetreatments[52].Tothebestof
our knowledge, no further trials with propranolol have
been published, but it is interesting to note that Alusi
and coworkers excluded two tremulous MS patients
from a thalamotomy trial because they had achieved
functional improvement after propranolol use [4].
In an open study the hypnotic-sedative drug glu-
tethimide exhibited visible functional beneﬁt in six of
eight MS patients with tremor [2]. Apparently, a
controlled trial to conﬁrm these ﬁndings was never
undertaken.
Two double-blind placebo-controlled trials using
isoniazid were published. In the ﬁrst study reduction
of tremor occurred in six of eight patients [16], with
functional improvement in four patients. In the sec-
ond study all six patients had measurable tremor
reduction after treatment with isoniazid but this did
not lead to functional improvement [44]. Doses of
isoniazid used to treat MS-related tremor were very
high (up to 1200 mg a day), and treatment was in some
patients associated with anorexia and nausea [38]o r
with a combination of drowsiness, dysphagia and in-
creased bronchial secretion. [32, 67] Other reported
side effects were abnormal liver function tests, [80, 32]
fatigue [32] and increased weakness [67]. Isoniazid
inhibits GABA aminotransferase activity and increases
GABA in the central nervous system, but no correla-
tion was found between the degree of GABA elevation
in the cerebrospinal ﬂuid and clinical response [16].
Sechi and coworkers published a small single-blind
placebo-controlled trial with carbamazepine [86].
They reported improvement of tremor as assessed by
clinical examination and accelerometry in all seven
included patients, but failed to report whether this
translated into functional improvement.
A placebo controlled, double-blind, crossover
study, suggested that a single intravenous dose of the
5-HT3 receptor antagonist ondansetron led to tremor
reduction in twelve, and to functional improvement in
nine of the sixteen included tremulous MS patients
[78]. A subsequent open label study by Gbadamosi
and colleagues which used the same intervention
found no signiﬁcant treatment effect [39]. Likewise, a
small clinical trial with dolasetron, another 5-HT3
receptor antagonist, showed no signiﬁcant treatment
effect on cerebellar ataxia [65].
Weiss and coworkers reported a positive effect of
intrathecal baclofen in a single patient with bilateral
arm tremor [96]. The tremor amplitude decreased
almost linearly as the dosage increased and tremor
was abolished at a dosage of 250 lg per day. This
possible treatment option has, however, not been
observed or evaluated in other studies.
In recent years, there has been growing interest in
cannabis as a possible therapeutic in MS. In the 1980’s
a case report [63] and a small uncontrolled study [21]
on the beneﬁcial effects of cannabis on tremor and
spasticity in MS were published and a survey taken
among MS patients revealed that many patients
experienced positive effects of smoked cannabis on
MS-related symptoms [23].
Baker and colleagues reported a decrease of tremor
and spasticity in an animal model of MS after treat-
ment with D
9-tetrahydrocannabinol, the active ingre-
dient of cannabis [12]. All this furthered hopes of
cannabis as a possible new treatment option for tre-
mor in MS, but much to the disappointment of
tremulous MS patients, several well conducted ran-
domized controlled trials did not show a signiﬁcant
effect of orally administered cannabis extracts [103,
37, 92] or oral D
9-tetrahydrocannabinol [103]o n
tremor.
j Surgical treatment
The surgical treatment options for tremor in MS are
stereotactic thalamotomy and DBS. An overview of
the published studies on surgical treatment is given in
Tables 3 and 4. Most of the studies are small obser-
vational retrospective studies. When reviewing the
literature on surgical treatment, it is surprising as well
as disappointing that the majority of studies are
remarkably imprecise in providing basic information
on the length of follow-up, on adverse effects and-
136Table 2 Studies on medical treatment of tremor in MS
Study n* study design intervention(s) tremor assessment patients
with
tremor
reduction
(%)
patients
with
improved
functional
status (%)
adverse effects (n)
Koller, 1984 [52] 3 double-blind placebo-
controlled crossover
propranolol (not speci-
fied) isoniazid (po.)
1200mg/d ethanol (iv.)
50ml of 10% solution
writing tasks, patient
self assessment, clinical
examination, accele-
rometry
no effect hepatitis while on iso-
niazid treatment (1)
Sabra et al. 1982 [80] 4 case reports isoniazid (po.) 400 to
1200mg/d
clinical examination 4 (100%) 4 (100%) abnormal liver function
tests (1)
Duquette et al.
1985 [32]
12 open label isoniazid (po.) 500–
1000mg/d
patient self assessment,
clinical examination,
blinded evaluation of
video tapes
10 (83%) 0 drowsiness, dysphagia,
increased bronchial
secretions (6) abnormal
liver function tests (2)
fatigue (2)
Morrow et al. 1985 [67] 5 open label isoniazid (po.) 700–
1200 mg/d
clinical examination 4 (80%) 4 (80%) increased weakness (2)
drowsiness (1)
Francis et al. 1986 [38] 5 open label isoniazid (po.) 1200
mg/d
clinical examination,
polarised light goniom-
etry
4 (80%) 0 anorexia and nausea
(3)
Hallet et al. 1985 [44] 6 double-blind placebo-
controlled crossover
isoniazid (po.) 1200
mg/d
self-rating scales,
accelerometry, blinded
evaluation of video
tapes
6 (100%) 0 None
Bozek et al. 1987 [16] 8 double-blind placebo-
controlled crossover
isoniazid (po.) 12 or 20
mg/kg
clinical examination,
accelerometry, blinded
evaluation of video
tapes
6 (75%) 4 (50%) somnolence (3) **
Sechi et al. 1989 [86] 7 single-blind placebo
controlled
carbamazepine (po.)
400 or 600 mg/d
clinical tremor rating
scale, accelerometry
7 (100%) not
reported
none reported
Rice et al. 1997 [78] 16 double-blind placebo-
controlled crossover
ondansetron (iv.) 8 mg
(single dose)
nine-hole peg-test,
writing tasks, patient
self assessment
12 (75%) not
reported
short-lasting foot
dystonia (1)
Gbadamosi et al.
2001 [39]
14 open label ondansetron (iv.) 8 mg
(single dose)
nine-hole peg-test,
writing tasks, patient
self assessment
no effect none reported
Aisen et al. 1991 [2] 6 open label Gluthetimide 750 to
1250 mg
blinded functional
assessment by occupa-
tional therapist, com-
puter-aided tracking
tasks
5 (83%) 5 (83%) sedation (4)
Clifford, 1983 [21] 8 open label D
9-THC (po.) 5 to 15
mg
clinical examination 5 (63%) 2 (25%) none
Zajicek et al.
2003 [103]
365  double-blind random-
ized placebo controlled
cannabis extract (po.)
D
9-THC (po.)
patient self assessment no effect cannabis extract:
adverse events in 12
D9-THC: adverse events
in18 placebo: adverse
events in 20
Wade et al. 2004 [92] 13  double-blind random-
ized placebo controlled
cannabis extract (po.) visual analogue scale
symptom reduction
no effect cannabis extract:$ 112
adverse events in 80
patients placebo:$ 53
adverse events in 80
patients
Fox et al. 2004 [37] 14 double-blind random-
ized placebo controlled
crossover
cannabis extract (po.) tremor rating scale no effect cannabis extract: ad-
verse events in 10
placebo: adverse events
in 2
THC = tetrahydrocannabinol
* MS patients completing the study
** in this study, one additional patient was withdrawn because of a severe adverse event (dyspnoea, fever, rash, obtundation)
  the main topic of the study is the effect of cannabinoids on spasticity in MS, the patients were asked to assess treatment effect on other symptoms
  in this study, patients were asked to name their most troublesome symptom; of the 160 included patients, 13 named tremor
$ No details are reported on the subgroup of the 13 tremulous patients, the total number of adverse events is reported for the whole groups on active treatment and
on placebo (80 patients in each group)
137Table 3 Studies on stereotactic surgery for the treatment of tremor in MS
Study n* patient
characteristics**
lesion site follow-up tremor and
disability
assessment
patients
with
tremor
reduction
(%)§
patients with
improved func-
tional status
(%)§
patients with
permanent
adverse effects (n)
Cooper, 1960a
[25]
2 disabling intention
tremor
VL 3 to 12 mo clinical examination 2 (100%) not reported none
Cooper, 1960b
[24]
6 disabling intention
tremor
unilateral (n = 5)
or bilateral (n = 1)
VL
Not specifically
reported
clinical examina-
tion, assessment of
filmed tremor
5 (83%) not reported increase of contra-
lateral hemiparesis
(1)
Krayenbu ¨hl et al.
1962 [54]
4 disabling bilateral
intention tremor
unilateral (n = 3)
or bilateral (n = 1)
VL
3 weeks to 6
mo
clinical examination 4 (100%) 4 (100%) none
Broager and Fog,
1962 [18]
4 severe intention
tremor
unilateral VL 1 to 6 mo clinical examination 4 (100%) 2 (50%) generalized seizure
(1) mental change
(1)
Cooper et al. 1967
[26]
32 disabling bilateral
intention tremor
unilateral or bilat-
eral VL
12 to 96 mo clinical examination 27 (85%) not reported increase of contra-
lateral hemiparesis
(2)
Samra et al. 1970
[81]
25 disabling bilateral
arm intention tre-
mor
unilateral or bilat-
eral VL
not specifically
reported
clinical examina-
tion, assessment of
filmed tremor
22 (88%) not reported increase of contra-
lateral hemiparesis
(1)
Riechert and
Richter, 1972 [79]
29 disabling intention
(n = 29) and pos-
tural (n = 18) tre-
mor
unilateral (n = 28)
or bilateral (n = 1)
VL
not specifically
reported
clinical examina-
tion, patient self
assessment ques-
tionnaires
29 (100%) ‘‘two thirds’’ of
patients
increase of leg
paresis (2)
Arsalo et al. 1973
[10]
26 disabling bilateral
intention tremor
unilateral VL and
subthalamus
3 to 97 mo clinical examination 21 (80%) not reported subdural haema-
toma (1)
Andrew et al.
1974 [8]
4 disabling postural
(n = 2) and inten-
tion (n = 4) tremor
unilateral VIM 6 to 36 mo clinical examination 4 (100%) not reported hemiplegia (1)
Van Manen, 1974
[91]
4 severe intention
tremor
unilateral VL 3 to 86 mo  clinical examination 2 (50%) not reported not reported sepa-
rately for MS sub-
group
Hauptvogel et al.
1975 [45]
11 severe intention
tremor
unilateral (n = 10)
or bilateral (n = 1)
VL
15 to 86 mo clinical examination 7 (63%) 4 (36%) not reported
Mundinger and
Kuhn 1982 [68]
84 severe action tre-
mor
ZI, VOP 36 to 120 mo clinical examination
filmed tremor pa-
tient self assess-
ment questionnaire
70 (83%) not reported not specifically re-
ported
Speelman and van
Manen, 1984 [89]
11 severe intention
tremor
unilateral VL 3 weeks to 132
mo
clinical tremor and
functional rating
scales
8 (73%) 0 (0%) hemiparesis (4)
micturition distur-
bance (2) speech
disorder (1)
Kandel and
Hondcarian, 1985
[51]
20 severe intention
tremor
unilateral (n = 15)
or bilateral (n = 5)
VL (ZI, FF)
12 to 120 mo not reported 14 (70%) not reported none
Hitchcock et al.
1987 [48]
30 tremor Thalamus 24 mo clinical examination
functional rating
scales
50% 25% not reported
Wester et al. 1990
[97]
9 severe intention
tremor
unilateral VOA and
VOP
3t o8 9m o
mean: 24 mo 
questionnaire sent
to treating neurol-
ogist
6 (66%) 6 (66%) hemiparesis (5)
mental changes (3)
dysphasia (3) dys-
arthria (2) subdural
haematoma (1)
Goldman et al.
1992 [43]
2 severe intention
tremor unrespon-
sive to medication
unilateral VL 3 mo 34 mo clinical tremor rat-
ing scale
2 (100%) 0 (0%) dysarthria (1)
Whittle and Had-
dow, 1995 [98]
9 severe rest, kinetic,
postural or inten-
tion tremor
unilateral VL 12 mo clinical examination
and evauation of
video tapes
9 (100%) 2 (22%) depression (2)
138most importantly-on the effect on functional status
and tremor associated disability.
The ﬁrst study on thalamotomy for tremor in MS
was published by Cooper in 1960 [25]. Brice and col-
leagues were the ﬁrst to report improvement of tremor
through continuous thalamic DBS in 1980 [17].
j Strategies for patient and treatment site
selection
The earlier studies on thalamotomy used the thalamic
nucleus ventralis lateralis (VL) as the target, whereas
the nucleus VIM was chosen in most DBS studies and
most later thalamotomy studies. This preference for
the VIM is probably due to the experience with this
thalamic nucleus in the treatment of tremor in Par-
kinson’s disease (PD) and essential tremor (ET). Re-
search groups in Oxford and London used the nucleus
VOP and the zona incerta (ZI) as targets for both
lesional surgery and DBS, but the results yielded with
these targets [4, 69, 15] were not different from those
reported for VIM or VL thalamotomy or stimulation.
The same researchers advocate the use of tremor
frequency analysis during movement tasks as a
method to identify patients likely to beneﬁt from
surgery [60]. This may be a valuable tool for patient
selection, although it has only been validated in a
Table 3 Continued
Study n* patient
characteristics**
lesion site follow-up tremor and
disability
assessment
patients with
tremor reduc-
tion (%)§
patients with
improved
functional
status (%)§
patients with
permanent
adverse effects (n)
Shahzadi et al.
1995 [87]
33 severe tremor unilateral VIM 3 to 120 mo clinical examination
ability to drink from
a waterfilled cup
22 (67%) 17 (51%) not reported
Hooper and Whit-
tle, 1998 [50]
6 severe postural
(n = 4) or inten-
tion tremor (n = 2)
unilateral VL 14 to 73 mo
mean: 51 mo
Barthel Index 1 (16%) 1 (16%) not reported
Critchley and
Richardson, 1998
[27]
24 disabling intention
tremor
unilateral (n = 22)
or bilateral (n = 2)
VIM
mean: 26 mo clinical tremor and
functional rating
scales
18 (75%) 2 (8%) hemiparesis (1) sei-
zure (2) MS relapse
(3) dysarthria (1)
Schuurman et al.
2000 [85]
5 severe arm tremor unilateral VIM  6 mo clinical tremor and
functional rating
scales
5 (100%) 0 (0%) severe gait or bal-
ance disturbance
(2)
Niranjan et al.
2000 [72]***
3 severe action tre-
mor
unilateral VIM 2 to 11 mo
median 6 mo 
clinical tremor rat-
ing scale, patient
self assessment of
functional improve-
ment
3 (100%) 3 (100%) none
Alusi et al. 2001
[4]
11 severe postural and
intention tremor
unilateral VOP
(n = 7), ZI (n = 3),
STN (n = 1)
12 mo clinical tremor and
functional rating
scales
11 (100%) 7 (64%) depression (3) sei-
zures (2) hemipare-
sis (1) dysphasia
(1)
Matsumoto et al.
2001 [62]
6 severe tremor unilateral VIM 3 to 12 mo clinical tremor and
functional rating
scales, novel move-
ment analysis tool
6 (100%) 0 (0%) MS relapse (2)
Bittar et al. 2005
[15]
10 disabling postural
and intention arm
tremor
unilateral VOP (dis-
tal tremor), unilat-
eral ZI (proximal
tremor) or unilat-
eral VOP and ZI
(mixed tremor)
12 to 50 mo:
mean 16 mo
clinical tremor rat-
ing scale
not individually
reported,
overall
improvement of
mean tremor
scores: postural:
78% intention:
72%
not
reported
hemiparesis (3) sei-
zures (1)
VOP = nucleus ventralis oralis posterior; VOA = nucleus ventralis oralis anterior; VIM = nucleus ventralis intermedius; ZI = zona incerta; VL = nucleus ventralis
lateralis; STN = nucleus subthalamicus; FF = Forel’s Field
* MS patients with completed surgical intervention and remaining in the study until end of follow up
** an effort is made to distinguish between predominance of intention or postural tremor although many terms to describe tremor subtypes are used in the studies
*** In this study, gamma-knife radiosurgery is used
§ improvement as described in case reports or measured at the end of follow-up on any scale used in the study
  in this study, MS patients were grouped together with patients with other movement disorders, no details are given for the MS-subgroup
  thalamotomy was followed six months later by contralateral DBS electrode implantation in patients with bilateral tremor
139Table 4 Studies on DBS for the treatment of tremor in MS
Study N* patient
characteristics
stimulation site follow-up tremor and
disability
assessment
patients
with
tremor
reduction
(%)§
patients with
improved
functional
status (%)§
patients with
permanent
adverse
effects (n)
Brice and McLe-
llan, 1980 [17]
2 severe bilateral arm
intention tremor
bilateral subtha-
lamic
5 mo 6 mo clinical exami-
nation
2 (100%) 2 (100%) **
Nguyen and De-
gos, 1993 [71]
1 severe unilateral
distal postural arm
tremor
unilateral VIM 17 mo clinical tremor
and functional
rating scales
1 (100%) 1 (100%) not reported
Siegfried and Lip-
pitz, 1994 [88]
9 severe intention
tremor
unilateral (n = 8)
or bilateral (n = 1)
VIM
not reported not reported 9 (100%) not reported not reported
Benabid et al.
1996 [13]
4 severe arm tremor  VIM  ‡ 6 mo clinical tremor
rating scale
0 (0%)  no detailed report  intracerebral
haemorrhage (1)
Geny et al. 1996
[41]
13 severe postural tre-
mor (n = 12),
moderate intention
tremor (n = 1)
unilateral VIM 8 to 26 mo
mean: 13 mo
clinical tremor
and functional
rating scales
9 (69%) 12 (92%) MS relapse (3)
Whittle et al. 1998
[99]***
5 severe arm tremor VL not reported not reported not re-
ported
not reported not reported
Hay, 1999 [46] 1 head and limb tre-
mor
unilateral thalamus 2 mo not reported 1 (100%) not reported not reported
Montgomery et al,
1999 [66]
14 disabling arm tre-
mor
unilateral VIM variable clinical tremor
rating scale
15 (100%) not reported MS relapse (1)#
Schulder et al.
1999 [83]
5 severe bilateral
postural and inten-
tion arm tremor
unilateral VIM >6 mo clinical tremor
rating scale,
patient self
assessment of
functional
improvement
5 (100%) 3 (60%) Ms relapse (2)
Taha et al. 1999
[90]
2 bilateral limb, head
or voice tremor 
bilateral VIM (bilat-
eral DBS or unilat-
eral DBS plus
contralateral tha-
lamotomy)
mean: 10 mo clinical tremor
rating scale
2 (100%) not reported not reported sepa-
rately for MS sub-
group 
Schuurman et al.
2000 [85]
5 severe arm tremor unilateral or bilat-
eral VIM
6 mo clinical tremor
and functional
rating scales
3–5 (60–
100%)$
0 (0%) dysarthria (2)
severe gait or bal-
ance disturbance
(1) arm ataxia (1)
Krauss et al. 2001
[53] Loher et al.
2003 [61]$$
2 severe tremor unilateral or bilat-
eral VIM 
3 to 24 mo,
mean: 12 mo 
clinical tremor
rating scales,
assessment of
video tapes
2 (100%) not reported not reported
separately for MS
subgroup 
Matsumoto et al.
2001 [62]
3 severe tremor unilateral VIM 3 to 12 mo clinical tremor
and functional
rating scales,
novel move-
ment analysis
tool
3 (100%) 0 (0%) none
Hooper et al. 2002
[49]
10 disabling arm tre-
mor
unilateral thalamus 12 mo clinical tremor
and functional
rating scales
10 (100%) 0 (0%) intracerebral haem-
orrhage (2) gener-
alized seizure (2)
Nandi et al. 2002
[70]
1 severe bilateral
postural and inten-
tion tremor
unilateral ZI 12 mo clinical exami-
nation
1 (100%) 1 (100%) increased dystonic
posturing of left
foot impairing
ambulation (1)
Berk et al. 2002
[14]
12 disabling arm tre-
mor
unilateral VIM 12 mo clinical tremor
and functional
rating scales,
patient self
assessment
questionnaire
significant
tremor
reduction,
not individ-
ually re-
ported
no significant
improvement
wound infection
(2)
Wishart et al.
2003 [102]
4 bilateral arm tremor bilateral VL 15 to 31 mo clinical tremor
rating scale
4 (100%) 4 (100%) MS relapse (1)
dysarthria (1)
140small number of patients and studies in which this
technique is used [4, 69, 15] do not report better re-
sults than studies without this selection method.
The site for lesional surgery or electrode placement
is classically chosen relative to the site of the anterior
and posterior commissures using a standardized atlas.
More recently, surgeons tried to reﬁne this placement
strategy with microelectrode recording within the
target area. Neurons discharging synchronous to
peripheral tremor are identiﬁed and the treatment site
is placed in an area where the most tremor related
neuronal activity is found. [73, 59, 57, 58]
This method of treatment site selection is often
used in studies on tremulous patients with PD and
ET, but only a small number of MS-patients were
included in these studies. [87, 13, 66, 62, 84] Since this
method offers a theoretical advantage over the clas-
sical methods of treatment site selection, it should be
further evaluated.
j Outcome after surgical treatment
Because of the many shortcomings of the published
studies, the results need to be interpreted with great
caution. It does, however, seem as if almost all pa-
tients experience tremor reduction immediately after
thalamotomy, and roughly 70% of patients continue
to beneﬁt from thalamotomy beyond a follow-up
period of one year (Table 3). In the three studies on
thalamic DBS with a follow-up period longer than one
year, 69% to 100% of the patients experienced
reduced tremor [41, 84, 102]. Functional improve-
ment after both thalamotomy and DBS is much more
variable and unfortunately not reported in many
studies (Tables 3 and 4).
Niranjan published an interesting study on gam-
ma-knife thalamotomy as a possible alternative to
neurosurgery. In this study all three patients with MS-
related tremor experienced marked improvement of
tremor after radiosurgery. Unfortunately, no further
studies have been published to evaluate this inter-
esting non-invasive treatment option [72].
There are two trials in which thalamotomy and
DBS were compared in patients with MS. In a ran-
domized controlled trial conducted by Schuurman
and colleagues [85] patients with ET, tremor due to
PD and tremulous MS patients were randomized to
undergo either VIM thalamotomy or DBS. Five
tremulous MS patients were randomized to each
Table 4 Continued
Study N* patient
characteristics
stimulation site follow-up tremor and
disability
assessment
patients with
tremor reduc-
tion (%)§
patients with
improved
functional
status (%)§
patients
with
permanent
adverse
effects (n)
Schulder et al. 2003
[84]
9 disabling arm
tremor
unilateral thalamus 9 to 48 mo, clinical tremor and
functional rating
scales, patient self
assessment
8 (88%) 3 (33%) MS relapse
(3)
Nandi et al. 2004 [69] 10 disabling arm
tremor
unilateral (n = 6)
or bilateral (n = 4)
VOP and ZI
3 to 23 mo computer-aided
tracking tasks
significant tre-
mor reduction,
not individually
reported
not reported seizure (1)
dysarthria
(1) wound
infection
(1)
Bittar et al. 2005 [15]y 10 disabling pos-
tural and
intention arm
tremor
unilateral VOP (dis-
tal tremor), unilat-
eral ZI (proximal
tremor) or unilat-
eral VOP and ZI
(mixed tremor)
3 to 23 mo: clinical tremor rat-
ing scale
not individually
reported, over-
all improve-
ment of mean
tremor scores:
postural: 64%
intention: 36%
not reported monopare-
sis (1)
VIM = nucleus ventralis intermedius; ZI = zona incerta; VL = nucleus ventralis lateralis
* MS patients with completed surgical intervention and remaining in the study until the end of follow up
§ improvement as described in case reports or measured at the end of follow-up on any scale used in the study
** in this study two patients had complete surgery and in three, surgery was aborted. A worsening of dysarthria is reported in one patient, it is unclear whether this
patients had completed surgery
*** This study mostly discusses difficulties in target localisation and patient selection
# in this study, one patient did not complete surgery due to an intraoperative VIM haemorrhage
  in this study, MS patients were grouped together with patients with other movement disorders, no details are given for the MS-subgroup
  For the whole group, tremor was ‘‘inconsistently, less significantly [than tremor of Parkinson’s Disease and essential tremor] or not improved. If improvement was
achieved it lasted only a few months’’
$ The exact number of patients with improved tremor cannot be ascertained the way the data is presented in this study
$$ Both studies are on one patient cohort, the relevant data on MS patients are derived from both studies
141group. After a short follow-up period of six months,
there were no signiﬁcant differences between
thalamotomy and DBS in functional outcome for the
MS subgroup. In the same study, fewer adverse effects
were observed in the DBS group, except for the sub-
group of MS patients, where adverse effects were
about equal for both interventions (Tables 3 and 4).
Bittar and colleagues compared cumulative tremor
scores for intention and postural tremor between
patients undergoing VOP/ZI thalamotomy or DBS in
a non-randomized study [15]. Ten patients were in
each group. Interestingly, after a mean follow-up
period of 15 to 16 months, patients in the thalamot-
omy group had a better outcome (tremor reduction:
78% for postural tremor and 72% for intention
tremor) than patients in the DBS group (tremor
reduction: 64% for postural tremor and 36% for
intention tremor). However, as there were more ad-
verse effects in the thalamotomy group, no clear
recommendations could be given.
Adverse events reported for the neurosurgical
interventions comprised increase of hemiparesis,
dysarthria, dysphasia, mental changes, depression,
seizures, intracerebral haemorrhage, subdural
haematoma, wound infection and MS relapse. Tha-
lamotomy was associated with a higher risk of adverse
events than DBS. Bilateral thalamotomy carries such a
high risk of adverse effects, that it is no longer rec-
ommended. If bilateral treatment is necessary, either
bilateral DBS or unilateral thalamotomy followed by
contralateral DBS are possible treatment options.
j Other treatment options
Electromagnetic ﬁelds, limb cooling, physiotherapy,
weight bracelets, orthoses and specialized software
have been advocated as additional treatment options.
Sandyk and Dann reported a reduction of intention
as well as postural tremor in three tremulous MS
patients treated with pulsed electromagnetic ﬁelds
[82], but these interesting ﬁndings have not been
substantiated in a larger trial.
Albrecht and coworkers published a small clinical
trial on the effect of arm cooling on intention tremor
[3]. In their study, patients achieved signiﬁcantly
better results on a clinical testing battery after
immersion of the tremulous arm in ice water. As this
effect lasted for about 45 minutes the authors rec-
ommend limb cooling to achieve transient tremor
control for activities such as working with a PC,
signing a document or self-catherisation. In a similar
study, Feys and colleagues report tremor reduction
lasting for about 30 minutes after limb cooling with a
special cooling device [35].
Weighted wrist cuffs are a mechanical tool to re-
duce tremor amplitude, and one article reported their
beneﬁcial effects in three MS patients [28]. Although
wearing bracelets decrease tremor amplitude and
therefore may offer some beneﬁt to tremulous pa-
tients, their effect on intention tremor is small and
their use is therefore unlikely to yield important
functional improvement. A more advanced computer
aided tremor reducing orthosis provided functional
beneﬁt in a small case series including patients with
MS [1].
Physiotherapy aimed at improving ataxia in MS
was evaluated by Armutlu and coworkers. In their
small pilot study they found that rehabilitative phys-
iotherapy using Johnstone pressure splints was
superior to physiotherapy alone [9]. Unfortunately no
larger trials followed this pilot study, so that it re-
mains uncertain which patients may beneﬁt from
which form of physiotherapy.
The use of a mouse driven computer system is a
special challenge for tremulous MS patients. Feys and
colleagues published a study on the use of specialized
software developed to aid computer use in 36 trem-
ulous MS patients and found signiﬁcant improvement
in the time needed to complete some basic mouse
driven computer operations [36].
Conclusion
The treatment of tremor remains a great challenge for
everyone caring for patients with MS. Drug treatment
with currently available medication is unsuccessful in
most cases and much more research on the patho-
physiology and biochemistry of tremor production in
MS will be necessary before an efﬁcient medical
treatment can be developed. Stereotactic surgery can
be an effective means to treat severe tremor, but it is
currently uncertain whether lesional surgery or DBS is
the treatment of choice. Larger clinical trials com-
paring both interventions are needed. Other treat-
ment options, including physiotherapy, tremor
reducing orthoses, and limb cooling can lead to
valuable improvements in activities of daily living.
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